Anthraquinone and its derivatives

Details Anthraquinone and its derivatives Anthraquinone and its derivatives

2006-03-06

2009-10-20

Riley, Jezia (Department: 1637)

Organic compounds -- part of the class 532-570 series

Organic compounds

Polycyclo ring system containing anthracene configured ring...

C552S237000, C552S240000, C435S004000, C435S006120, C514S644000

Reexamination Certificate

active

07605280

ABSTRACT:
There is disclosed a compound of formula (I) wherein each of X1and X2are independently NH-A-NR1R2, and wherein A is A C2-8alkylene and R1and R2are independently selected from hydrogen, C1-4alkyl, C2-4hydroxy-alkyl and C2-4aminoalkyl, or R1and R2together form a C2-6alkylene group which with the nitrogen atom to which R1and R2are attached forms a heterocyclic ring, or an N-oxide derivative thereof, and wherein the compound (I) or its N-oxide derivative is optionally in the form of an acid salt derived from an organic or inorganic acid. Also disclosed is a method of its production and its uses, including its use in analyzing a cell or biological material and detecting the emitted fluorescence signal.

REFERENCES:
patent: 4410524 (1983-10-01), Murdock
patent: 5132327 (1992-07-01), Patterson
patent: 6468753 (2002-10-01), Smith
patent: 2 237 283 (1991-05-01), None
patent: WO 91 05824 (1991-05-01), None
Paul J. Smith et al., “Flow Cytometric Analysis and Confocal Imaging of Anticancer Alkylaminoathraquinones and Their N-Oxides in Intact Human Cells Using 647-nm Krypton Laser Excitation,” Cytometry, vol. 27, No. 1, 1997, pp. 43-53.
Paul J. Smith et al., “DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides,” Cancer Chemotherapry and Pharmacology, vol. 39, No. 5, 1997, pp. 455-461.
Laurence H. Patterson, “Rationale for use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent,” Cancer and Metastatis Reviews, vol. 12, 1993, pp. 119-134.
WR Wilson et al., “Tertiary anime N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N,” British Journal of Cancer, vol. 74, 1996, pp. 43-47.
Laurence H. Patterson et al., “Aliphatic Amine N-oxides of DNA Binding Agents as Bioreductive Drugs,” Oncology Research, V. 6, 1994, pp. 533-538.
SR McKeown et al, “AQ4N: an Alkylaminoanthraquinone N-oxide Showing Bioreductive Potential and Positive Interaction with Radiation in vivo,” British Journal of Cancer, 72, 1995 pp. 76-81.
SR McKeown et al., “Evidence for a Therapeutic Gain when AQ4N or Tirapazamine is Combined with Radiation,” British Journal of Cancer, 74, 1996, pp. S39-S42.
MV Hejmadi et al., “DNA Damage Following Combination of Radiation with the Bioreductive Drug AQ4N: Possible Selective Toxicity to Oxic and Hypoxic Tumour Cells,” British Journal of Cancer, 73, 1996, pp. 499-505.

Affiliated with

Also associated with

Rating

Anthraquinone and its derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anthraquinone and its derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anthraquinone and its derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4055052